Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on November 16, 2017. The registrant is a Delaware corporation and has elected to be treated as an emerging growth company. The report addresses a specific corporate governance event regarding executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on personnel changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the departure of a senior officer:
- Robert Hadfield resigned as General Counsel, effective November 29, 2017.
- The resignation is to pursue other opportunities.
- Mr. Hadfield will remain an advisor to the Company for up to three months following his termination.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the standard disclosure of the officer's departure.
Investor Verification Checklist
- Verify the identity of the registrant (Flex Pharma, Inc.) to ensure it matches the intended investment target.
- Confirm the appointment of a new General Counsel or interim legal leadership to replace Robert Hadfield.
- Review subsequent filings for any impact of this departure on ongoing legal matters or corporate strategy.